IP Library Granted Patent US 10,758,601
Granted Patent B2
US 10,758,601 · App. 16/471,057 · Granted Sep 1, 2020

Eimeria vaccine with improved efficacy

Inventors: Alex Shepherd (Northampton, GB); Colin Crouch (High Wycombe, GB)
Assignee: Intervet Inc.
A61K39/012A61P31/04A61K2039/55561
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,758,601
App. No.
16/471,057
Granted
Sep 1, 2020
Kind
B2
Abstract

The present invention relates to the fields of veterinary parasitology and -vaccinology; more specifically the invention relates to a composition comprising live Eimeria oocysts and a pharmaceutically acceptable carrier. The composition is characterised in that it comprises a TLR3 agonist. The composition can be used to prepare a vaccine for poultry against Coccidiosis. The vaccine can be applied for example as a coarse spray on day-old chicks. The TLR3 agonist in the vaccine allows for a reduction of the dose of Eimeria oocysts up to 4 fold, while obtaining the same level of protection against challenge as from a vaccine without the TLR3 agonist. Alternatively, when employing a conventional dose of Eimeria oocysts in the vaccine, the TLR3 agonist causes an earlier onset of immunity, resulting in a significant reduction of the intestinal lesion score upon challenge, already at 2 instead of at 3 weeks after vaccination.

Claims (12)

1. A composition comprising live Eimeria oocysts and a pharmaceutically acceptable carrier, wherein the composition further comprises between about 0.3 and about 5% w/v Xanthan gum and a TLR3 agonist.

2. The composition of claim 1 , wherein the TLR3 agonist is poly A:U.

3. The composition of claim 1 , wherein the live Eimeria oocysts are sporulated oocysts.

4. The composition of claim 1 , wherein the live Eimeria oocysts are selected from the group consisting of: E. tenella, E. acervulina, E. maxima, E. mitis, E. necatrix, E. brunetti, E. praecox, E. mivati, E. hagani, E. meleagrimitis 1 , E. meleagrimitis 2 , E. adenoeides, E. gallopavonis, E. dispersa , and any combination thereof.

5. The composition of claim 1 , wherein the composition further comprises between about 0.1 and about 1.6% w/v of a metal salt.

6. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable colorant.

7. A method for the preparation of a composition comprising live Eimeria oocysts, a pharmaceutically acceptable carrier, and a TLR3 agonist comprising admixing live Eimeria oocysts and a pharmaceutically acceptable carrier, with a TLR3 agonist.

8. The composition of claim 1 , comprising 0.3-1.5% w/v Xanthan gum, and having a viscosity of between 200-4000 mPa·s.

9. A method of vaccinating poultry against Coccidiosis, comprising administering the composition of claim 1 to said poultry.

10. The method of vaccinating of claim 9 , comprising administering the vaccine by coarse spray onto the poultry and/or onto their surroundings.

11. A method for the reduction of an infection with Eimeria in poultry, or of associated signs of disease, comprising administering the composition of claim 1 to said poultry.

12. A method for the delivery of a TLR3 agonist to an avian gut by an oral route, wherein the TLR3 agonist is admixed with a Xanthan gum.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2019
From: SHEPHERD, ALEX; CROUCH, COLIN
To: INTERVET INC.
Reel/Frame 049515/0628 →
Priority Claims (1)
EP 16206058 · Dec 22, 2016 · regional
Continuity (1)
Related Publication 20190328858A1 · Oct 31, 2019